



IHIF Statement on COVID-19 Response

As state and local officials grapple with community concerns on keeping Hoosiers safe, we must also recognize the important role that Indiana's biopharmaceutical and medical device manufacturers play in keeping the country protected during the outbreak of COVID-19.

There are over 1,700 companies in Indiana involved in the production and development of critical devices, diagnostic tests, and biopharmaceutical products and their components. Collectively, they employ over 59,000 workers – a workforce trained to comply with strict regulatory requirements for clean room production and worker personal safety and protection.

As state officials contemplate increasing the level of response and potentially implementing new, "Shelter in Place," restrictions to control the spread of the virus, ***we encourage them to make the appropriate exemptions for those businesses and employees involved in the production of critical medical and biopharmaceutical products.*** These entities include manufacturers, distributors, suppliers and servicers of medical devices, diagnostics, biopharmaceuticals, and related ingredients, equipment, and services, including health care delivery. This should be broadly construed to also include all other supplies and services required to maintain critical health care supply chain operations without disruption.

It is crucial that all entities with the ability to contribute to the global cause do so. This will allow current and future patients to access needed health care products and technologies and ensure that physicians and providers have the tools they need to diagnose and treat patients.

[3/18/2020]